This content is from: Features

Do India’s compulsory licences violate TRIPs?

The compulsory licence issued to Natco over Bayer’s Nexavar drug in India and Novartis’s case at the Supreme Court could set a precedent for developing countries’ approach to pharma patents. Peter Roderick and Pravin Anand take contrasting positions on the cases

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here

Instant access to all of our content. Membership Options | 30 Day Trial